Volume 25, Issue 113, July 2021

Laboratory investigation and clinical outcomes in sickle cell disease patients infected with COVID-19: A single-center experience in India

Sunmeet Matkar^1♦, Ajit Gangawane²

¹PhD Scholar, Parul Institute of Applied Sciences , Parul University, Vadodara, Gujarat- 391760 & Life Wave Diagnostic and Research Centre, Mumbai, Maharashtra, India
²Professor, Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat- 391760, India

^♦Corresponding author
PhD Scholar, Parul Institute of Applied Sciences , Parul University, Vadodara, Gujarat- 391760 & Life Wave Diagnostic and Research Centre, Mumbai, Maharashtra, India

ABSTRACT

Background: Patients with sickle cell disease (SCD) have been part of the population 'high-risk' group since the COVID‐19 pandemic. This study focused to understand impact ofCOVID-19 on clinical outcomes in SCD. Methods: Data were taken at the baseline and clinical course of this prospective one-center intervention in SCD patients diagnosed with COVID-19 in isolation centers (associated with Sevagram Hospital) dedicated for COVID-19 patients in Wardha, Maharashtra, India. Patients were followed uppost-hospital discharge for up to 1 month. Results: Of 120 SCD patients with COVID-19, 88 patients (73.33%) required hospitalization, and 32 died (26.67%). Vasocclusive pain was the most common symptom. In 36.36% of hospitalised people and all those who died, acute chest syndrome occurred. Older and recent hypertension records, congestion and stroke, and elevated levels of creatinine and bilirubin were common among patients who died. Conclusion: The risk for morbidity, including ACS, seems the greatest among older patients with sickle cell status, particularly those who have chronic end-organ diseases, including brain, heart and lung

Keywords: COVID-19, Sickle cell disease, India, Hematology

Medical Science, 2021, 25(113), 1522-1529

PDF